JP2010505930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505930A5 JP2010505930A5 JP2009531915A JP2009531915A JP2010505930A5 JP 2010505930 A5 JP2010505930 A5 JP 2010505930A5 JP 2009531915 A JP2009531915 A JP 2009531915A JP 2009531915 A JP2009531915 A JP 2009531915A JP 2010505930 A5 JP2010505930 A5 JP 2010505930A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pain
- acid addition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 178
- 150000003839 salts Chemical class 0.000 claims description 80
- 239000002253 acid Substances 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 69
- 208000002193 Pain Diseases 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 24
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 12
- 239000003429 antifungal agent Substances 0.000 claims description 11
- 229940121375 antifungal agent Drugs 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 208000004454 Hyperalgesia Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000003096 antiparasitic agent Substances 0.000 claims description 5
- 229940125687 antiparasitic agent Drugs 0.000 claims description 5
- 239000003904 antiprotozoal agent Substances 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 229910052723 transition metal Inorganic materials 0.000 claims description 5
- 150000003624 transition metals Chemical class 0.000 claims description 5
- 230000029812 viral genome replication Effects 0.000 claims description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000035154 Hyperesthesia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 4
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 208000035868 Vascular inflammations Diseases 0.000 claims description 4
- 206010047095 Vascular pain Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012346 acetyl chloride Substances 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 206010053552 allodynia Diseases 0.000 claims description 4
- 208000037849 arterial hypertension Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 230000000552 rheumatic effect Effects 0.000 claims description 4
- 208000004371 toothache Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- 241000223960 Plasmodium falciparum Species 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000005905 mesyloxy group Chemical group 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CC(C)c(cc(C(N(C1)Cc2c1ccc(CN1CCN(*)CC1)c2)=O)c(O)c1)c1O Chemical compound CC(C)c(cc(C(N(C1)Cc2c1ccc(CN1CCN(*)CC1)c2)=O)c(O)c1)c1O 0.000 description 21
- 239000013078 crystal Chemical group 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- PBWGTOOLBHCMNP-UHFFFAOYSA-N CC(C)c(cc(C(N(C1)Cc2c1ccc(CNCCNC)c2)=O)c(O)c1)c1O Chemical compound CC(C)c(cc(C(N(C1)Cc2c1ccc(CNCCNC)c2)=O)c(O)c1)c1O PBWGTOOLBHCMNP-UHFFFAOYSA-N 0.000 description 2
- KERQOIXKIUJGQE-UHFFFAOYSA-N CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=C Chemical compound CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=C KERQOIXKIUJGQE-UHFFFAOYSA-N 0.000 description 2
- RDWLGPMLGHAUIC-UHFFFAOYSA-N CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=O Chemical compound CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=O RDWLGPMLGHAUIC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- ALPBVTMNNRPKOJ-UHFFFAOYSA-N CC(c(c(O)c1)cc(C(OC)=O)c1O)=O Chemical compound CC(c(c(O)c1)cc(C(OC)=O)c1O)=O ALPBVTMNNRPKOJ-UHFFFAOYSA-N 0.000 description 1
- IIFCLXHRIYTHPV-UHFFFAOYSA-N COC(c(ccc(O)c1)c1O)=O Chemical compound COC(c(ccc(O)c1)c1O)=O IIFCLXHRIYTHPV-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical group [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82924306P | 2006-10-12 | 2006-10-12 | |
| GB0620259.2 | 2006-10-12 | ||
| US60/829.243 | 2006-10-12 | ||
| GBGB0620259.2A GB0620259D0 (en) | 2006-10-12 | 2006-10-12 | Pharmaceutical compounds |
| PCT/GB2007/003871 WO2008044034A1 (en) | 2006-10-12 | 2007-10-12 | Hydrobenzamide derivatives as inhibitors of hsp90 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505930A JP2010505930A (ja) | 2010-02-25 |
| JP2010505930A5 true JP2010505930A5 (enExample) | 2011-12-22 |
| JP5726416B2 JP5726416B2 (ja) | 2015-06-03 |
Family
ID=37491396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531915A Active JP5726416B2 (ja) | 2006-10-12 | 2007-10-12 | Ｈｓｐ９０の阻害剤としてのヒドロベンズアミド誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8653084B2 (enExample) |
| EP (2) | EP2081895B1 (enExample) |
| JP (1) | JP5726416B2 (enExample) |
| KR (1) | KR101571568B1 (enExample) |
| CN (1) | CN101848892B (enExample) |
| AU (1) | AU2007306104B2 (enExample) |
| BR (1) | BRPI0719879A8 (enExample) |
| CA (1) | CA2665931C (enExample) |
| CY (2) | CY1113873T1 (enExample) |
| DK (2) | DK2081895T3 (enExample) |
| ES (2) | ES2662359T3 (enExample) |
| GB (1) | GB0620259D0 (enExample) |
| HR (2) | HRP20130255T1 (enExample) |
| HU (1) | HUE037268T2 (enExample) |
| IL (1) | IL197934A (enExample) |
| LT (1) | LT2546233T (enExample) |
| ME (1) | ME01874B (enExample) |
| MX (1) | MX2009003739A (enExample) |
| NO (1) | NO342242B1 (enExample) |
| NZ (1) | NZ576110A (enExample) |
| PL (2) | PL2546233T3 (enExample) |
| PT (2) | PT2081895E (enExample) |
| RS (2) | RS57079B1 (enExample) |
| RU (1) | RU2490258C2 (enExample) |
| SI (2) | SI2546233T1 (enExample) |
| TW (1) | TWI429638B (enExample) |
| WO (1) | WO2008044034A1 (enExample) |
| ZA (1) | ZA200902270B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2332909E (pt) | 2005-04-13 | 2014-12-17 | Astex Therapeutics Ltd | Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2073807A1 (en) * | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5798115B2 (ja) | 2009-06-22 | 2015-10-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 置換ヒドロキサム酸およびその使用 |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| BR112014019704B1 (pt) * | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| KR20150010793A (ko) * | 2012-05-25 | 2015-01-28 | 버그 엘엘씨 | 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 |
| US20180169117A1 (en) | 2014-03-20 | 2018-06-21 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical formulation comprising a substituted phenyl - (1,3-dihydro-isoindol-2-yl) - methanone |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CA3168495A1 (en) * | 2020-01-20 | 2021-07-29 | Neophore Limited | Isoindoline derivatives which bind to an atp binding site |
| CN114767683A (zh) * | 2022-04-29 | 2022-07-22 | 暨南大学 | Onalespib在制备预防和/或治疗腺病毒感染的药物中的应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5540563Y2 (enExample) | 1972-04-26 | 1980-09-22 | ||
| JPS4910506A (enExample) | 1972-05-31 | 1974-01-30 | ||
| US4582909A (en) | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4760064A (en) | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| CA1340191C (en) | 1988-06-13 | 1998-12-15 | Katsuhiro Imaki | Derivatives of p-substituted phenyl ester of pivalic acid |
| US4990511A (en) | 1988-08-03 | 1991-02-05 | Takeda Chemical Industries, Ltd. | Amide compounds, their production and use |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5124350A (en) | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| ZA916555B (en) | 1990-08-27 | 1993-04-28 | Lilly Co Eli | Method of treating inflammatory bowel disease |
| FR2669029B1 (fr) | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5280046A (en) | 1991-02-22 | 1994-01-18 | The University Of Colorado Foundation, Inc. | Method of treating type I diabetes |
| WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
| US5619092A (en) * | 1993-02-01 | 1997-04-08 | Motorola | Enhanced electron emitter |
| US5633283A (en) | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
| JPH0910506A (ja) | 1995-06-30 | 1997-01-14 | Toshiba Corp | 脱気器 |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| JP3855026B2 (ja) | 1996-01-16 | 2006-12-06 | 富士レビオ株式会社 | アミド誘導体の製造方法 |
| DE69739970D1 (de) | 1996-01-29 | 2010-10-07 | Univ California | Methode zur behandlung sexueller fehlfunktionen |
| GB9606187D0 (en) | 1996-03-23 | 1996-05-29 | Inst Of Food Research | Production of vanillin |
| WO1997036876A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU714477B2 (en) | 1996-04-19 | 2000-01-06 | Regents Of The University Of California, The | Treatment of mood/affective disorders by glutamatergic upmodulators |
| IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
| JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | ４，５，６，７−テトラヒドロ−チエノ［３，２−ｃ］ピリジン誘導体類、それらの製造方法及び使用 |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| JP2001526643A (ja) | 1997-04-18 | 2001-12-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環 |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| ES2258825T3 (es) | 1997-10-27 | 2006-09-01 | Cortex Pharmaceuticals, Inc. | Tratamiento de la esquizofrenia con ampakinas y neurolepticos. |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| WO2000059867A1 (en) | 1999-03-30 | 2000-10-12 | Pharmacor Inc. | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| DE19955283A1 (de) | 1999-11-17 | 2001-05-23 | Aventis Res & Tech Gmbh & Co | Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| AU2001243158A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| DE10024939A1 (de) | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| MXPA03001654A (es) | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| WO2003051877A1 (en) | 2001-12-18 | 2003-06-26 | Bayer Corporation | 2-substituted pyrrolo[2.1-a]isoquinolines against cancer |
| AU2002366811B2 (en) | 2001-12-20 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Pyrimidine A2B selective antagonist compounds, their synthesis and use |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| US20030203915A1 (en) | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
| TW200410671A (en) | 2002-06-05 | 2004-07-01 | Inst Med Molecular Design Inc | Medicines for inhibiting the activation of AP-1 |
| CN101103977A (zh) | 2002-06-05 | 2008-01-16 | 株式会社医药分子设计研究所 | 糖尿病治疗药 |
| AU2003242131A1 (en) | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
| CN1658872B (zh) | 2002-06-06 | 2010-09-22 | 株式会社医药分子设计研究所 | 抗过敏药 |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| NZ537853A (en) | 2002-07-16 | 2007-02-23 | Amura Therapeutics Ltd | Inhibitors of cathepsin K and related cysteine protesases of the CA clan |
| EP1554271A1 (en) | 2002-10-15 | 2005-07-20 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| TWI228885B (en) | 2003-01-23 | 2005-03-01 | Mediatek Inc | Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode |
| EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| CN1764375A (zh) | 2003-02-20 | 2006-04-26 | 康涅狄格大学健康中心 | 使用包括热休克蛋白或α－2－巨球蛋白的组合物治疗癌症和传染病的方法 |
| EP1597256A1 (en) | 2003-02-21 | 2005-11-23 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| EP1599475A2 (en) | 2003-03-06 | 2005-11-30 | Eisai Co., Ltd. | Jnk inhibitors |
| EP1622866B1 (en) | 2003-04-30 | 2012-07-25 | Novartis AG | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| KR101129215B1 (ko) | 2003-06-27 | 2012-04-13 | 교와 핫꼬 기린 가부시키가이샤 | Ｈｓｐ90 패밀리 단백질 저해제 |
| TWI312345B (en) | 2003-06-30 | 2009-07-21 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
| JPWO2005007151A1 (ja) | 2003-07-16 | 2006-08-31 | 株式会社医薬分子設計研究所 | 皮膚色素沈着の治療剤 |
| CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| ZA200510137B (en) | 2003-07-24 | 2007-04-25 | Leo Pharma As | Novel aminobenzophenone compounds |
| AU2004261610B2 (en) | 2003-07-28 | 2010-05-20 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators |
| DE10335584B4 (de) | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Verfahren zur Herstellung zyklischer Moleküle |
| DE10335726A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
| WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
| CA2572750A1 (en) | 2003-09-10 | 2005-03-17 | Anil Koul | Heterobicyclic compounds as pharmaceutically active agents |
| CN103145715B (zh) | 2003-10-14 | 2016-08-03 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
| BRPI0415874A (pt) | 2003-11-10 | 2007-01-09 | Schering Ag | compostos de amina de éter benzìlico como antagonistas de ccr-5 |
| EP1704856A4 (en) | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
| US7351709B2 (en) | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| JP2008508303A (ja) | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
| KR20070046180A (ko) | 2004-08-20 | 2007-05-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도 |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| EP1813270A4 (en) | 2004-11-09 | 2009-07-01 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITORS OF THE HSP90 FAMILY |
| EP1817295B1 (en) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| HRP20100076T1 (hr) | 2005-02-07 | 2010-03-31 | F. Hoffmann - La Roche Ag | Heterociklički supstituirani fenil metanoni kao inhibitori glicin transportera 1 |
| WO2006088954A1 (en) | 2005-02-15 | 2006-08-24 | Janssen Pharmaceutica, N.V. | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| CA2599046A1 (en) | 2005-02-21 | 2006-08-24 | Kyowa Hakko Kogyo Co., Ltd. | Antitumor agent |
| PT2332909E (pt) | 2005-04-13 | 2014-12-17 | Astex Therapeutics Ltd | Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90 |
| WO2006117669A1 (en) | 2005-05-03 | 2006-11-09 | Pfizer Inc. | Amide resorcinol compounds |
| AU2006247136C1 (en) | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| US7425633B2 (en) | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| PT1808634E (pt) * | 2006-01-12 | 2008-12-11 | Ondal Holding Gmbh | Acessório de fixação para suportar um dispositivo |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
-
2006
- 2006-10-12 GB GBGB0620259.2A patent/GB0620259D0/en not_active Ceased
-
2007
- 2007-10-11 TW TW096138174A patent/TWI429638B/zh not_active IP Right Cessation
- 2007-10-12 DK DK07824125.4T patent/DK2081895T3/da active
- 2007-10-12 EP EP07824125A patent/EP2081895B1/en active Active
- 2007-10-12 LT LTEP12187611.4T patent/LT2546233T/lt unknown
- 2007-10-12 HU HUE12187611A patent/HUE037268T2/hu unknown
- 2007-10-12 PT PT78241254T patent/PT2081895E/pt unknown
- 2007-10-12 RU RU2009117589/04A patent/RU2490258C2/ru not_active IP Right Cessation
- 2007-10-12 JP JP2009531915A patent/JP5726416B2/ja active Active
- 2007-10-12 SI SI200732010T patent/SI2546233T1/en unknown
- 2007-10-12 AU AU2007306104A patent/AU2007306104B2/en not_active Ceased
- 2007-10-12 CA CA2665931A patent/CA2665931C/en not_active Expired - Fee Related
- 2007-10-12 ME MEP-2013-34A patent/ME01874B/me unknown
- 2007-10-12 RS RS20180350A patent/RS57079B1/sr unknown
- 2007-10-12 HR HRP20130255TT patent/HRP20130255T1/hr unknown
- 2007-10-12 ES ES12187611.4T patent/ES2662359T3/es active Active
- 2007-10-12 CN CN2007800455503A patent/CN101848892B/zh not_active Expired - Fee Related
- 2007-10-12 EP EP12187611.4A patent/EP2546233B1/en active Active
- 2007-10-12 PL PL12187611T patent/PL2546233T3/pl unknown
- 2007-10-12 PL PL07824125T patent/PL2081895T3/pl unknown
- 2007-10-12 DK DK12187611.4T patent/DK2546233T3/en active
- 2007-10-12 RS RS20130118A patent/RS52716B/sr unknown
- 2007-10-12 MX MX2009003739A patent/MX2009003739A/es active IP Right Grant
- 2007-10-12 KR KR1020097009666A patent/KR101571568B1/ko not_active Expired - Fee Related
- 2007-10-12 ES ES07824125T patent/ES2402903T3/es active Active
- 2007-10-12 BR BRPI0719879A patent/BRPI0719879A8/pt not_active Application Discontinuation
- 2007-10-12 PT PT121876114T patent/PT2546233T/pt unknown
- 2007-10-12 US US12/445,130 patent/US8653084B2/en not_active Expired - Fee Related
- 2007-10-12 WO PCT/GB2007/003871 patent/WO2008044034A1/en not_active Ceased
- 2007-10-12 SI SI200731206T patent/SI2081895T1/sl unknown
- 2007-10-12 NZ NZ576110A patent/NZ576110A/en not_active IP Right Cessation
-
2009
- 2009-04-01 ZA ZA2009/02270A patent/ZA200902270B/en unknown
- 2009-04-05 IL IL197934A patent/IL197934A/en active IP Right Grant
- 2009-05-12 NO NO20091858A patent/NO342242B1/no not_active IP Right Cessation
-
2013
- 2013-04-03 CY CY20131100278T patent/CY1113873T1/el unknown
-
2014
- 2014-01-07 US US14/149,450 patent/US9428439B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 HR HRP20180375TT patent/HRP20180375T1/hr unknown
- 2018-03-19 CY CY20181100318T patent/CY1120081T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505930A5 (enExample) | ||
| RU2009117589A (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| CN107286077B (zh) | 一种选择性的c-kit激酶抑制剂 | |
| TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
| WO2017048954A1 (en) | Hepatitis b core protein modulators | |
| EA027476B1 (ru) | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости | |
| JP6630364B2 (ja) | 水溶性プロドラッグ | |
| EP2615092B1 (en) | Heterocyclic amino berbamine derivatives, preparation method and use thereof | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP6940504B2 (ja) | 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法 | |
| JP2008538779A5 (enExample) | ||
| CN107513067A (zh) | 含有取代环戊基的吡咯并嘧啶化合物 | |
| CN119110795A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| TW200813066A (en) | Novel compounds | |
| JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| TW201815793A (zh) | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| JP2024507822A (ja) | Ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）－ベンズアミドの本質的に純粋な形態ｉｖの組成物及びその使用 | |
| US10428008B2 (en) | Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions | |
| JP2011516444A (ja) | Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体 | |
| JP2023002841A (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| EP4442684A1 (en) | A class of pyrimidine compounds, and preparation method therefor and use thereof | |
| JPWO2020169736A5 (enExample) | ||
| JP2022522539A (ja) | キナーゼ阻害剤の多形体、このような化合物を含有する医薬組成物、調製方法、および適用 | |
| JP7611593B2 (ja) | Ｈｄａｃ分解剤 |